SAN DIEGO, Feb. 28, 2012 /PRNewswire/ -- Organovo, Inc.
(OTCQB: ONVO) has been included in the 2012 TR50, Technology
Review's annual list of the world's most innovative technology
companies, for three-dimensional (3D) bioprinting
technology. TR50 members are nominated by Technology
Review's editors, who look for companies that over the last
year have demonstrated original and valuable technology, are
bringing that technology to market at a significant scale, and are
clearly influencing their competitors. Spanning energy, computing,
the Web, biomedicine, and materials, the companies on the list
represent commercial innovations most likely to change lives around
the world.
"Organovo is opening the door to a new realm of medical
advances. The company's ability to print three dimensional tissue
structures will lead to better testing of new drugs and may one day
find direct applications in replacing damaged tissue in patients,"
said Jason Pontin, editor in chief
and publisher of Technology Review.
Organovo is focused on breakthrough 3D bioprinting technology to
create tissue on demand for research and medical applications. The
company's NovoGen MMX BioprinterTM is part of a 3D
human tissue generation platform that works across a broad array of
tissue and cell types to recapitulate in vivo biology. Organovo's
bioprinting technology has immediate applications in disease
research, drug discovery and development, and toxicology
testing. In the future, applications of this technology hold
the promise to generate tissues for therapeutic
uses.
"The immediate use of Organovo's 3D bioprinting technology is to
create tissues to test drugs in a truly human biological
environment and improve today's drug discovery and development for
pharmaceutical and biotech companies," said Keith Murphy, chairman and CEO of Organovo. "We
are driven to continue innovating the technology and working with
leaders in the field to fulfill the promise of 3D bioprinting for
research and medical applications."
Organovo will be presenting at RetailInvestorConferences.com, an
interactive real-time virtual conference. The webcast will
take place on March 1, 2012 at
10 a.m. PST. To take part,
please register at www.retailinvestorconferences.com. An
on-demand archive will be available for 90 days.
About Technology Review, Inc.
Technology Review is an independent media company owned by
the Massachusetts Institute of
Technology. More than three million people around the globe
read our publications, in five languages and on a variety of
digital and print platforms. We publish Technology Review
magazine, the world's oldest technology magazine (established
1899); daily news, analysis, opinion, and video on
www.technologyreview.com and several mobile apps; Business
Impact, which explains how new technologies are transforming
companies, disrupting markets, or creating entirely new industries;
and live events including the annual Emtech MIT conference.
Technology Review also owns the MIT Enterprise Forum, a community
and events organization that fosters technology entrepreneurship
with 28 chapters worldwide.
About Organovo Inc.
Organovo, Inc. (OTCQB: ONVO) is a three-dimensional biology
company focused on delivering breakthrough bioprinting technology
and creating tissue on demand for research and medical
applications. The company's NovoGen three-dimensional bioprinting
technology is a platform that works across all tissue and cell
types. Organovo's NovoGen MMX Bioprinter was selected as one of the
"Best Inventions of 2010" by TIME Magazine. Organovo is helping
pharmaceutical partners develop human biological disease models in
three dimensions that enable therapeutic drug discovery and
development. Organovo's bioprinting technology can also be
developed to create surgical tissues direct therapy. Organovo leads
the way in solving complex medical research problems and building
the future of medicine. The company is headquartered in
San Diego, California. For
more information, please visit http://www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products based on its technology; the expected benefits
and efficacy of the Company's products and technology; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and, the
Company's business, research, product development, regulatory
approval, marketing and distribution plans and strategies. These
and other factors are identified and described in more detail in
our filings with the SEC, including, our current reports on Form
8-K. We do not undertake to update these forward-looking statements
made by us.
SOURCE Organovo, Inc.
